Omnicell, Inc. 2006 Annual Report (10-K) Summary
Business Context and Reporting Period
This report covers the fiscal year ended December 31, 2006. Omnicell, Inc. is a leading provider of medication control and patient safety solutions for acute care health facilities. The company designs and sells automated hardware and software systems for controlling, dispensing, acquiring, verifying, and tracking medications and medical/surgical supplies. The primary market is the United States, with sales also occurring through distributors in Europe, Asia, Australia, and the Middle East.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Total Revenues | $154.7 million | $121.5 million |
| Gross Profit | $85.5 million (55.3% margin) | $67.0 million (55.1% margin) |
| Net Income | $10.4 million | ($2.1 million) loss |
| Diluted EPS | $0.36 | ($0.08) |
| Cash and Cash Equivalents | $60.9 million | $29.5 million |
| Operating Cash Flow | $19.5 million | ($1.9 million) used |
| Product Backlog | $114.0 million | $69.6 million |
| Total Assets | $154.6 million | $100.4 million |
| Long-term Obligations | $11.1 million | $11.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 27.3% to $154.7 million, driven by increased unit volume sales of medication and supply automation systems and new customer relationships.
- Profitability Turnaround: The company returned to profitability with $10.4 million in net income, reversing a $2.1 million net loss in 2005. This was aided by operational leverage and improved efficiencies.
- Share-Based Compensation: The company adopted SFAS No. 123(R) in 2006, resulting in a non-cash expense of $8.1 million. Without this charge, net income would have been higher.
- Backlog Expansion: Product backlog grew 63.8% to $114.0 million, indicating strong demand outpacing installation capacity.
- Inventory Build: Inventory increased to $15.7 million (from $13.8 million) as the company increased finished goods levels to meet installation schedules.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects revenue growth to continue in 2007 but anticipates gross margins may decline due to market price reductions and share-based compensation expenses, potentially offset by revenue growth and cost reductions.
- Internal Control Material Weakness: Management and the independent auditor (Ernst & Young) identified a material weakness in internal controls over financial reporting. This pertained to the timely review of reconciliations and account balances, specifically impacting lease receivables, inventories, and share-based compensation. This resulted in a revision of 2006 quarterly financial data.
- Legal Proceedings: The company is a defendant in a product liability lawsuit (Alcala et al. v. Cardinal Health, Inc.) alleging that a defect in an Omnicell product contributed to a patient's death. Omnicell denies liability and intends to defend vigorously.
- Key Risks: Significant risks include intense competition (notably from Pyxis/Cardinal Health), dependence on a limited number of suppliers (including a new single-source sub-assembly manufacturer), and the potential for government funding cuts affecting U.S. government customers.
Investor Verification Checklist
- Internal Control Remediation: Verify the specific steps taken in 2007 to remediate the material weakness in financial reporting controls identified in 2006.
- Backlog Conversion: Monitor the rate at which the $114 million backlog is converted into recognized revenue, given the long installation cycles (up to 12 months).
- Supplier Concentration: Assess the risks associated with the new single-source third-party manufacturer for hardware sub-assemblies and the status of securing secondary sites.
- Share-Based Compensation Impact: Evaluate the ongoing impact of SFAS 123(R) on future earnings and the company's strategy to manage this expense.
- Legal Exposure: Track the status of the Alcala product liability lawsuit and potential insurance coverage implications.